Show simple item record

dc.contributor.authorRomero Sánchez, Consuelo
dc.contributor.authorRobinson, William H.
dc.contributor.authorTomooka, Beren H.
dc.contributor.authorLondoño, John
dc.contributor.authorValle Oñate, Rafael
dc.contributor.authorHuang, Feng
dc.contributor.authorDeng, Xiaohu
dc.contributor.authorZhang, Liyun
dc.contributor.authorYang, Chunhua
dc.contributor.authorTak Yan Yu, David
dc.date.accessioned2020-09-04T21:32:19Z
dc.date.available2020-09-04T21:32:19Z
dc.date.issued2008-06-20
dc.identifier.citationRomero-Sánchez, C., Robinson, W.H., Tomooka, B.H. et al. Identification of acute phase reactants and cytokines useful for monitoring infliximab therapy in ankylosing spondylitis. Clin Rheumatol 27, 1429–1435 (2008). https://doi.org/10.1007/s10067-008-0941-xes_CO
dc.identifier.otherhttps://pubmed.ncbi.nlm.nih.gov/18566849/
dc.identifier.otherhttps://link.springer.com/article/10.1007%2Fs10067-008-0941-x#citeas
dc.identifier.urihttp://hdl.handle.net/10818/43203
dc.description8 páginases_CO
dc.description.abstractAlthough most ankylosing spondylitis patients show an apparent clinical response to infliximab therapy, there is considerable individual variation. Because current clinical assessment relies heavily on subjective patient self-evaluation, biomarkers of high sensitivity and specificity are much needed. Here, we assessed potential biomarkers in 47 ankylosing spondylitis patients who received three standard pulses of infliximab. Before each infusion and at week 10, the following were measured: erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), platelet count, serum levels of metalloproteinase-3 (MMP-3), and 22 different cytokines. We discovered that, 2 weeks after the first infusion, the combination of ESR, CRP, and platelet count distinguished responders from non-responders with 81.3% sensitivity and 72.7% specificity. The distinguishing power was much less when each acute phase reactant was used alone. Among the 22 cytokines, serum IL-1alpha was able to distinguish responders from non-responders at week 6, with sensitivity of 84.9% and specificity of 53.8%. Serum IL-1alpha was probably generated from the joint compartments, as synovial fluid levels were much higher than corresponding serum levels. Although infliximab infusions led to rapid and significant suppression of serum MMP-3 levels, serum MMP-3 levels did not distinguish responders from non-responders. Besides identifying potential biomarkers, our results also demonstrate the usefulness of using sensitivity and specificity to assess usefulness of potential biomarkers.es_CO
dc.formatapplication/pdfes_CO
dc.language.isoenges_CO
dc.publisherClinical Rheumatologyes_CO
dc.relation.ispartofseriesClinical Rheumatology volume 27, pages1429–1435(2008)
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.sourceinstname:Universidad de La Sabanaes_CO
dc.sourcereponame:Intellectum Repositorio Universidad de La Sabanaes_CO
dc.subjectAnkylosing spondylitises_CO
dc.subjectBiomarkerses_CO
dc.subjectInfliximabes_CO
dc.titleIdentification of acute phase reactants and cytokines useful for monitoring infliximab therapy in ankylosing spondylitises_CO
dc.typearticlees_CO
dc.type.hasVersionpublishedVersiones_CO
dc.rights.accessRightsopenAccesses_CO
dc.identifier.doihttps://doi.org/10.1007/s10067-008-0941-x


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 InternationalExcept where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International